Joana Goncalves has been named chief medical officer of Cara Therapeutics (NASDAQ: [[ticker:CARA]]). She comes to the Stamford, CT, company from Celgene (NASDAQ: [[ticker:CELG]]), where she was vice president, medical affairs for dermatology and neurology. Cara’s lead drug candidate, difelikefalin (Korsuva), is in late-stage testing as a treatment for chronic itching associated with chronic kidney disease.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
